- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| NEUROSENSE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 29.06. | NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS | 146 | PR Newswire | First randomized, double-blind, placebo-controlled trial to demonstrate treatment-associated reduction of TDP-43 in people living with ALS
TDP-43 pathology is... ► Artikel lesen | |
| 25.06. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 25.06. | NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease | 275 | PR Newswire | PrimeC was associated with changes across multiple biomarkers spanning key neurodegenerative disease pathways, providing early biological evidence consistent with... ► Artikel lesen | |
| 18.06. | Halberd Corp.: Halberd Corporation Ships Latest NeuroSense AI Version, Advancing Voice-Based Behavioral Monitoring | 3 | GlobeNewswire (USA) | ||
| 08.06. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 24.04. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 03.04. | NeuroSense Therapeutics receives Nasdaq notices over listing requirements | 20 | Seeking Alpha | ||
| 03.04. | NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements | 271 | PR Newswire | Notifications have no immediate effect on the listing or trading of the Company's securities on Nasdaq
Nasdaq has provided the Company until September 29, 2026... ► Artikel lesen | |
| 31.03. | NeuroSense Therapeutics reports FY results, GAAP EPS of $0.44 | 2 | Seeking Alpha | ||
| 31.03. | NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update | 487 | PR Newswire | 2025 marked transition of PrimeC into a late-stage clinical asset with FDA-cleared Phase 3 program in ALS
Statistically significant survival benefit demonstrated... ► Artikel lesen | |
| 31.03. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 31.03. | NeuroSense Therapeutics Ltd. - 20-F, Annual and transition report of foreign private issuers | 2 | SEC Filings | ||
| 24.03. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 16.03. | NeuroSense: JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity | 371 | PR Newswire | The Journal of the American Medical Association (JAMA Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase... ► Artikel lesen | |
| 11.03. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
| 10.03. | Roth/MKM initiates NeuroSense stock with buy on ALS drug potential | 5 | Investing.com | ||
| 18.02. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 09.02. | Neurosense-Aktie legt nach Patent-Erfolg in Australien zu | 2 | Investing.com Deutsch | ||
| 09.02. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 6,570 | -4,51 % | Novavax (NVAX) Registers a Bigger Fall Than the Market: Important Facts to Note | ||
| PALATIN TECHNOLOGIES | 7,610 | 0,00 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| OCUGEN | 1,068 | -4,81 % | Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa | Cumulative sales milestones up to $255 million and modest upfront/near-term development milestonesRoyalties equaling 22% of net salesOcugen to manufacture and supply OCU400 MALVERN, Pa., July 13,... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,300 | -4,76 % | NurExone: Exosomen-Technologie springt vom Labor in den Wellnessmarkt! | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,200 | -2,12 % | Druck auf Pacific Biosciences nimmt zu: Warum die Geduld der Anleger auf eine harte Probe gestellt wird | Pacific Biosciences gerät zunehmend unter Druck: Die Aktie steht nach einer "significant downward revision of revenue guidance" und dem erzwungenen Aktienrückzug eines Großaktionärs im Fokus. Für Investoren... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,088 | +2,06 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
20.07.2026 / 16:41 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,633 | -4,19 % | RedHill Biopharma Ltd.: RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation | The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,383 | -2,55 % | Onco-Innovations Ltd: Onco-Innovations begins studies to develop ONC010 | ||
| NOVOCURE | 16,390 | -6,72 % | Novocure Reports Second Quarter 2026 Financial Results | Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications
CE Mark received for Optune Paxfor the treatment of locally... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 7,600 | 0,00 % | Citizens reiterates Ocular Therapeutix stock rating on Dextenza sales | ||
| ROCKET PHARMACEUTICALS | 2,830 | -2,08 % | Aktien New York: Weitere Verluste - Iran-Krieg und China-News belasten | NEW YORK (dpa-AFX) - Die US-Aktienmärkte haben am Freitag ihre Talfahrt fortgesetzt. Der anhaltende Iran-Krieg und die weiter steigenden Ölpreise mahnen die Anleger zur Vorsicht. Auf die Stimmung drückte... ► Artikel lesen | |
| PALISADE BIO | 1,950 | 0,00 % | Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2 | ||
| ONCOLYTICS BIOTECH | 0,813 | 0,00 % | FDA grants fast track status to Oncolytics' anal cancer therapy | ||
| OUTLOOK THERAPEUTICS | 1,264 | +10,20 % | Outlook Therapeutics, Inc. - 8-K, Current Report | ||
| REGENXBIO | 8,600 | -4,40 % | Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments |
NEUROSENSE THERAPEUTICS LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,515 Euro und damit +0,98 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEUROSENSE THERAPEUTICS LTD finden Sie auf Wallstreet Online.